Last reviewed · How we verify
sevoflurane 1
sevoflurane 1 is a Small molecule drug developed by Konkuk University Medical Center. It is currently in Phase 1 development.
Sevoflurane is a small molecule that acts as a positive modulator of the glycine receptor (alpha-1/beta). It is used in clinical trials to study various conditions, including postoperative pain, emergence agitation, and cognitive dysfunction.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | sevoflurane 1 |
|---|---|
| Sponsor | Konkuk University Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Low-flow Versus Minimal-flow Sevoflurane Anesthesia During Robot-assisted Laparoscopic Radical Prostatectomy (NA)
- Equivalent MAC in General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium (PHASE4)
- Low-Flow Desflurane vs Sevoflurane: Impact on Physiology and Recoveryand Recovery Profiles in Adult ENT Surgery (NA)
- Low-Flow Sevoflurane and Desflurane Anesthesia in Laparoscopic Cholecystectomy (NA)
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sevoflurane 1 CI brief — competitive landscape report
- sevoflurane 1 updates RSS · CI watch RSS
- Konkuk University Medical Center portfolio CI
Frequently asked questions about sevoflurane 1
What is sevoflurane 1?
Who makes sevoflurane 1?
What development phase is sevoflurane 1 in?
Related
- Manufacturer: Konkuk University Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing